Busulfan + Fludarabine + Cyclophosphamide + Anti-Thymocyte Globulin (Rabbit) + G-CSF
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fanconi Anemia
Conditions
Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Trial Timeline
May 15, 2018 → Apr 9, 2021
NCT ID
NCT03600909About Busulfan + Fludarabine + Cyclophosphamide + Anti-Thymocyte Globulin (Rabbit) + G-CSF
Busulfan + Fludarabine + Cyclophosphamide + Anti-Thymocyte Globulin (Rabbit) + G-CSF is a phase 2 stage product being developed by Brain Biotech for Fanconi Anemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03600909. Target conditions include Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03600909 | Phase 2 | Terminated |
Competing Products
4 competing products in Fanconi Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Etanercept | Amgen | Phase 1 | 32 |
| RP-L102 | Rocket Pharmaceuticals | Phase 2 | 44 |
| RP-L102 | Rocket Pharmaceuticals | Phase 1 | 25 |
| RP-L102 | Rocket Pharmaceuticals | Phase 2 | 44 |